Stock Details
REGN is Regeneron Pharmaceuticals, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 736.96$. Average daily volumn in 3 months 651.99k. Market cap 81.96B



Stock symbol : REGN. Exchange : NasdaqGS. Currency : USD
Lastest price : 749.66$. Total volume : 617.66k. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

Regeneron Pharmaceuticals, Inc. (REGN)
Last Price
749.66$
Change
-20.28
Volume
617.66k

Previous Close769.94
Open766.34
Day Range748.12-768.26
Bid740.54 x 800
Ask750.26 x 4k
Volume617.66k
Average Volume651.99k
Market Cap81.96B
Beta0.24
52 Week Range538.01-800.48
Trailing P/E19.89
Foward P/E16.62
Dividend (Yield %)N/A
Ex-Dividend DateN/A



Financial Details


According to Regeneron Pharmaceuticals, Inc.'s financial reports the company's revenue in 2022 were 12.17B an decrease(-25%) over the years 2021 revenue that were of 16.07B. In 2022 the company's total earnings were 4.34B while total earnings in 2021 were 8.08B(-50%).


Loading ...



Organization

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo inje... ction to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Market Cap:
81.96B
Revenue:
12.17B
Total Assets:
29.21B
Total Cash:
3.11B


News about "Regeneron Pharmaceuticals, Inc."

regeneron-pharmaceuticals-inc-nasdaqregn-q4-2022-earnings-call-transcript-image

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2022 Earnings Call Transcript

Source from : YAHOO!Finance - 3 days ago

Q4 2022 Earnings Call February 3, 2023 Operator: Welcome to the Regeneron Pharmaceuticalsโ€™ Fourth Quarter 2022 Earnings Conference Call. My name is Shannon and I will be your operator for todayโ€™s call ...See details»


regeneron-shares-rise-as-eczema-drug-sales-help-drugmaker-post-q4-earnings-beat-image

Regeneron shares rise as eczema drug sales help drugmaker post Q4 earnings beat

Source from : Investing.com on MSN - 5 days ago

By Scott Kanowsky Investing.com -- Shares in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rose on Friday after the drugmaker posted better-than-expected earnings in the fourth quarter despite a dip in ...See details»


regeneron-pharmaceuticals-inc-stock-outperforms-market-on-strong-trading-day-image

Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day

Source from : MarketWatch - 8 days ago

Shares of Regeneron Pharmaceuticals Inc. rose 2.99% to $758.47 Tuesday, on what proved to be an all-around positive trading session for the stock ...See details»


are-investors-undervaluing-regeneron-pharmaceuticals-inc-nasdaqregn-by-31-image

Are Investors Undervaluing Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) By 31%?

Source from : YAHOO!Finance - 7 days ago

Today we will run through one way of estimating the intrinsic value of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by projecting its future cash flows and then discounting them to today's value. We ...See details»


regeneron-pharmaceuticals-inc-stock-outperforms-market-despite-losses-on-the-day-image

Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day

Source from : MarketWatch - 9 days ago

Shares of Regeneron Pharmaceuticals Inc. slipped 0.86% to $736.46 Monday, on what proved to be an all-around dismal trading session for the stock ...See details»


Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Source from : Yahoo - 28 days ago

With its stock down 7.1% over the past three months, it is easy to disregard Regeneron Pharmaceuticals (NASDAQ:REGN). However, stock prices are usually driven by a companyโ€™s financial ...See details»


Regeneron Pharma Q4 Profit Declines; Adj. Total Revenues Up 14%

Source from : Business Insider - 5 days ago

Regeneron Pharmaceuticals, Inc. (REGN) reported fourth-quarter adjusted profit per share of $12.56compared to $23.42, prior year. On ...See details»


Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) insiders who sold earlier this year may be offered solace in this recent price drop

Source from : Yahoo - 1 month ago

Even though Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has fallen by 3.5% over the past week , insiders who sold US$7.0m worth of stock over the past year have had less luck. The average ...See details»


Regeneron Pharmaceuticals Inc.

Source from : Wall Street Journal - 1 year ago

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...See details»


Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?

Source from : Nasdaq - 9 days ago

Regeneron Pharmaceuticals, Inc. REGN is scheduled to release fourth-quarter 2022 results on Feb 3, before the opening bell. The company has an impressive track record having beaten earnings in all ...See details»


Regeneron Pharmaceuticals, Inc. Common Stock (REGN)

Source from : Nasdaq - 3 years ago

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...See details»


Regeneron: Q4 Earnings Snapshot

Source from : Houston Chronicle - 6 days ago

The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $9.68 per share. The biopharmaceutical company posted revenue of $3.41 billion in the period, also ...See details»


Regeneron Stock

Source from : Profit Confidential - 5 years ago

On Thursday January 5, a U.S Federal judge ruled that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR)(NYSE:SNY) have infringed onโ€ฆ Regeneron Pharmaceuticals Inc: Trump's ...See details»


Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their decent 94% return over the last five years

Source from : Yahoo! Sports - 24 days ago

For example, the Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) share price is up 94% in the last 5 years, clearly besting the market return of around 37% (ignoring dividends). On the other hand ...See details»